Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)-Reference-Cited by-同舟云学术

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Published:2014-03-13 Issue:11 Volume:123 Page:1665-1673
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chang Julie E.¹,Li Hailun²,Smith Mitchell R.³,Gascoyne Randy D.⁴,Paietta Elisabeth M.⁵,Yang David T.¹,Advani Ranjana H.⁶,Horning Sandra J.⁷,Kahl Brad S.¹

Affiliation:

1. University of Wisconsin, Madison, WI;

2. Dana Farber Cancer Institute, Boston, MA;

3. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;

4. British Columbia Cancer Agency, Vancouver, BC, Canada;

5. The North Division of Montefiore Medical Center, Bronx, NY;

6. Stanford University, Stanford, CA; and

7. Genentech, Inc., South San Francisco, CA

Abstract

Key Points VcR-CVAD produced high overall and CR rates in previously untreated MCL patients. No substantial difference in 3-year PFS or OS was observed in patients receiving ASCT compared with patients receiving maintenance rituximab.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/11/1665/537237/1665.pdf

Reference42 articles.

1. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.;Howard;J Clin Oncol,2002

2. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).;Lenz;J Clin Oncol,2005

3. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG Trial.;Hoster;ASH Annual Meeting Abstracts,2008

4. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.;Kahl;Ann Oncol,2006

5. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.;Romaguera;J Clin Oncol,2005

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL;Blood;2024-09-05

2. Development of Proteasome Inhibitors for Cancer Therapy;International Journal of Drug Discovery and Pharmacology;2024-03-18

3. SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-09

4. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation;Haematologica;2023-08-31

5. Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide;Journal of Clinical Oncology;2023-01-20